Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

Published on Jul 1, 2019in Lancet Oncology33.752
· DOI :10.1016/S1470-2045(19)30167-6
Howard Jack West15
Estimated H-index: 15
Michael McCleod17
Estimated H-index: 17
(Sarah Cannon Research Institute)
+ 17 AuthorsFederico Cappuzzo78
Estimated H-index: 78
(AUSL: Academy for Urban School Leadership)
Summary Background Atezolizumab (a monoclonal antibody against PD-L1), which restores anticancer immunity, improved overall survival in patients with previously treated non-small-cell lung cancer and also showed clinical benefit when combined with chemotherapy as first-line treatment of non-small-cell lung cancer. IMpower130 aimed to assess the efficacy and safety of atezolizumab plus chemotherapy versus chemotherapy alone as first-line therapy for non-squamous non-small-cell lung cancer. Methods IMpower130 was a multicentre, randomised, open-label, phase 3 study done in 131 centres across eight countries (the USA, Canada, Belgium, France, Germany, Italy, Spain, and Israel). Eligible patients were aged 18 years or older, and had histologically or cytologically confirmed stage IV non-squamous non-small-cell lung cancer, an Eastern Cooperative Oncology Group performance status of 0 or 1, and received no previous chemotherapy for stage IV disease. Patients were randomly assigned (2:1; permuted block [block size of six] with an interactive voice or web response system) to receive atezolizumab (1200 mg intravenously every 3 weeks) plus chemotherapy (carboplatin [area under the curve 6 mg/mL per min every 3 weeks] plus nab-paclitaxel [100 mg/m 2 intravenously every week]) or chemotherapy alone for four or six 21-day cycles followed by maintenance therapy. Stratification factors were sex, baseline liver metastases, and PD-L1 tumour expression. Co-primary endpoints were investigator-assessed progression-free survival and overall survival in the intention-to-treat wild-type (ie, EGFR wt and ALK wt ) population. The safety population included patients who received at least one dose of the study drug. This study is registered with, number NCT02367781. Findings Between April 16, 2015, and Feb 13, 2017, 724 patients were randomly assigned and 723 were included in the intention-to-treat population (one patient died before randomisation, but was assigned to a treatment group; this patient was excluded from the intention-to-treat population) of the atezolizumab plus chemotherapy group (483 patients in the intention-to-treat population and 451 patients in the intention-to-treat wild-type population) or the chemotherapy group (240 patients in the intention-to-treat population and 228 patients in the intention-to-treat wild-type population). Median follow-up in the intention-to-treat wild-type population was similar between groups (18·5 months [IQR 15·2–23·6] in the atezolizumab plus chemotherapy group and 19·2 months [15·4–23·0] in the chemotherapy group). In the intention-to-treat wild-type population, there were significant improvements in median overall survival (18·6 months [95% CI 16·0–21·2] in the atezolizumab plus chemotherapy group and 13·9 months [12·0–18·7] in the chemotherapy group; stratified hazard ratio [HR] 0·79 [95% CI 0·64–0·98]; p=0·033) and median progression-free survival (7·0 months [95% CI 6·2–7·3] in the atezolizumab plus chemotherapy group and 5·5 months [4·4–5·9] in the chemotherapy group; stratified HR 0·64 [95% CI 0·54–0·77]; p vs 65 [28%] of 232 in the chemotherapy group), anaemia (138 [29%] vs 47 [20%]), and decreased neutrophil count (57 [12%] vs 19 [8%]). Treatment-related serious adverse events were reported in 112 (24%) of 473 patients in the atezolizumab plus chemotherapy group and 30 (13%) of 232 patients in the chemotherapy group. Treatment-related (any treatment) deaths occurred in eight (2%) of 473 patients in the atezolizumab plus chemotherapy group and one ( Interpretation IMpower130 showed a significant and clinically meaningful improvement in overall survival and a significant improvement in progression-free survival with atezolizumab plus chemotherapy versus chemotherapy as first-line treatment of patients with stage IV non-squamous non-small-cell lung cancer and no ALK or EGFR mutations. No new safety signals were identified. This study supports the benefit of atezolizumab, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer. Funding F. Hoffmann-La Roche.
📖 Papers frequently viewed together
201960.39The Lancet
249 Authors (Tony Mok, ..., Alfred Zippelius)
993 Citations
201660.39The Lancet
19 Authors (Roy S. Herbst, ..., Edward B. Garon)
3,609 Citations
307 Citations
Abstract Background Standard first-line therapy for metastatic, squamous non–small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. Methods In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metast...
1,264 CitationsSource
#1Louis Fehrenbacher (KP: Kaiser Permanente)H-Index: 69
#2Joachim von PawelH-Index: 60
Last. Fabrice Barlesi (AMU: Aix-Marseille University)H-Index: 71
view all 23 authors...
Abstract Introduction The efficacy and safety of atezolizumab versus the efficacy and safety of docetaxel as second- or third-line treatment in patients with advanced NSCLC in the primary (n = 850) and secondary (n = 1225) efficacy populations of the randomized phase III OAK study (respectively referred to as the intention-to-treat [ITT] 850 [ITT850] and ITT1225) at an updated data cutoff were assessed. Methods Patients received atezolizumab, 1200 mg, or docetaxel, 75 mg/m2, intravenously every ...
114 CitationsSource
#1Muhammad Sohaib Khan (Guangzhou Medical University)H-Index: 1
#2Jie Lin (Guangzhou Medical University)H-Index: 7
Last. Yawei Yuan (Guangzhou Medical University)H-Index: 3
view all 8 authors...
AbstractBackground:Recently, immune checkpoint inhibitors have shown survival advantage over chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). This meta-analysis was conducted to gather and analyze the available evidence (Evidence level I; Randomized Controlled Trials) co
46 CitationsSource
: Cancer immunotherapy (CIT) has transformed cancer treatment. In particular, immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 pathway have demonstrated durable clinical benefit in some patients. However, CIT combinations may create a more favorable environment in which to maximize the potential of the immune system to eliminate cancer. Here we describe 3 key mechanisms related to vascular endothelial growth factor (VEGF)-mediated immunosuppression: inhibition o...
71 CitationsSource
#1Toyoaki HidaH-Index: 67
#2Reiko KajiH-Index: 21
Last. Toshio Kubo (Okayama University)H-Index: 18
view all 10 authors...
Abstract Introduction Atezolizumab, an anti–programmed death-ligand 1 (PD-L1) agent, is effective and well tolerated in patients with pretreated advanced non–small-cell lung cancer (NSCLC). We assessed its efficacy and safety in Japanese patients through subgroup analyses of the phase 3 OAK study ( NCT02008227 ). Patients and Methods Key eligibility criteria of this randomized, controlled, open-label, international study include locally advanced/metastatic NSCLC, ≥ 1 prior platinum-based chemoth...
35 CitationsSource
#1Mark A. SocinskiH-Index: 77
#2Robert M. JotteH-Index: 22
Last. Martin ReckH-Index: 78
view all 20 authors...
Abstract Background The cancer-cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non–small-cell lung cancer (NSCLC) who had not previously received chemotherapy. Methods We randomly assigned patients to receive atezolizumab plus carboplatin plus paclitaxel (ACP), beva...
1,433 CitationsSource
#1Mark A. SocinskiH-Index: 77
#2Robert M. JotteH-Index: 22
Last. Martin ReckH-Index: 78
view all 19 authors...
9002Background: Atezo (anti–PD-L1) inhibits PD-L1 to restore anticancer immunity; bev may enhance atezo efficacy by inhibiting VEGF immunosuppression and promoting T-cell tumor infiltration. IMpowe...
63 CitationsSource
#1Leena Gandhi (NYU: New York University)H-Index: 51
Last. Marina Chiara GarassinoH-Index: 41
view all 29 authors...
Abstract Background First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the first-line treatment of choice. The addition of pembrolizumab to chemotherapy resulted in significantly higher rates of response and longer progression-free survival than chemotherapy alone ...
2,339 CitationsSource
#1Achim RittmeyerH-Index: 21
#2Fabrice Barlesi (AMU: Aix-Marseille University)H-Index: 71
Last. David R. Gandara (UC Davis: University of California, Davis)H-Index: 99
view all 25 authors...
Summary Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer. Methods We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries. We enrolled patients who had squamo...
2,379 CitationsSource
#1David J. SmithH-Index: 155
#2Johan Vansteenkiste (Katholieke Universiteit Leuven)H-Index: 90
Last. Alexander I. SpiraH-Index: 30
view all 18 authors...
9028Background: Atezolizumab (atezo, MPDL3280A), a humanized engineered mAb, is the first anti-PD-L1 agent to show improved OS vs docetaxel (doc) in NSCLC. These results correlate with PD-L1 expres...
19 CitationsSource
Cited By394
#1Jordi RemonH-Index: 27
#2Francesco Facchinetti (Institut Gustave Roussy)H-Index: 20
Last. Benjamin Besse (Université Paris-Saclay)H-Index: 78
view all 3 authors...
The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and improved overall survival reaching almost one-third of patients alive at 5 years. ICIs therapies have also modified the therapeutic strategy in first-line setting in metastatic small-cell lung cancer (SCLC) patients as well as in malignant pleural mesoth...
#1Golnaz Morad (University of Texas MD Anderson Cancer Center)H-Index: 12
#2Beth A. Helmink (WashU: Washington University in St. Louis)H-Index: 8
Last. Jennifer A. Wargo (University of Texas MD Anderson Cancer Center)H-Index: 85
view all 4 authors...
Unprecedented advances have been made in cancer treatment with the use of immune checkpoint blockade (ICB). However, responses are limited to a subset of patients, and immune-related adverse events (irAEs) can be problematic, requiring treatment discontinuation. Iterative insights into factors intrinsic and extrinsic to the host that impact ICB response and toxicity are critically needed. Our understanding of the impact of host-intrinsic factors (such as the host genome, epigenome, and immunity)...
#1Taisuke Araki (Shinshu University)H-Index: 1
#2Yoshiaki Kitaguchi (Shinshu University)H-Index: 14
Last. Masayuki Hanaoka (Shinshu University)H-Index: 28
view all 8 authors...
Background null The quantity of skeletal muscles has recently been reported to have prognostic value in patients with non-small-cell lung cancer (NSCLC) treated with second-line immunotherapy. However, the prognostic role of skeletal muscle assessment in NSCLC patients undergoing first-line immuno-oncology (IO) combinatorial treatment (IO-chemotherapy) has not been elucidated. null Methods null We retrospectively reviewed 36 patients with NSCLC undergoing first-line IO-chemotherapy between April...
Abstract null null Background null The genomic mutation and immune feature landscape of ERBB2 exon 20 insertion (ERBB2-ex20ins)-driven non-small cell lung cancer and the features associated with the response to chemoimmunotherapy are currently unknown. null null null Methods null The genomic landscape of ERBB2-ex20ins lung adenocarcinoma (LUAD) patients was characterized by next-generation sequencing (NGS) of 1021 cancer genes. The clinical outcomes of chemoimmunotherapy were evaluated among 13 ...
#1Giannis MountziosH-Index: 24
Last. Sofia Baka (Interbalkan Medical Center)H-Index: 13
view all 42 authors...
Background null The advanced lung cancer inflammation index [ALI: body mass index × serum albumin/neutrophil-to-lymphocyte ratio (NLR)] reflects systemic host inflammation, and is easily reproducible. We hypothesized that ALI could assist guidance of non-small-cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICIs). null null null Patients and methods null This retrospective study included 672 stage IV NSCLC patients treated with programmed death-ligand 1 (PD-L1) inhibitors a...
#1M. ReckH-Index: 28
Last. O. Juan-VidalH-Index: 8
view all 27 authors...
Background null To further characterize survival benefit with first-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone, we report updated data from the phase III CheckMate 9LA trial with a 2-year minimum follow-up. null null null Patients and methods null Adult patients were treatment naive, with stage IV/recurrent non-small-cell lung cancer, no known sensitizing EGFR/ALK alterations, and an Eastern Cooperative Oncology Group performance status ≤1. Patients ...
#1Vincent Lemaire (Genentech)H-Index: 6
#2Colby S. Shemesh (Genentech)H-Index: 10
Last. Anand RotteH-Index: 20
view all 3 authors...
The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the development of combination therapies with anti-PD-1/PD-L1 blockers as a backbone. As more and more drugs with translational potential are identified, the number of clinical trials evaluating combinations has increased considerably and the demand to prioritize combinations having potential for succ...
#1Yoon Jin Cha (Yonsei University)H-Index: 16
#2Dooreh Kim (Catholic University of Korea)
Last. Chang Ik Yoon (Catholic University of Korea)H-Index: 6
view all 10 authors...
Immune checkpoint inhibitors (ICI) have demonstrated efficacy in the treatment of solid cancers. However, there is no unified predictive biomarker available for ICIs. We aimed to compare the prognostic impact of using three PD-L1 antibodies (SP142, SP263, and 22C3) for immunohistochemical (IHC) analysis. We retrospectively investigated tumor tissues derived from 316 breast cancer cases, by constructing tissue microarrays and by performing IHC staining. The immune-cell expression rate (for SP142 ...
#1Tomonari KinoshitaH-Index: 9
#2Hideki TeraiH-Index: 11
Last. Tomonori Yaguchi (Kyoto University)H-Index: 1
view all 3 authors...
The three major conventional treatments: surgery, chemotherapy, and radiation therapy, have been commonly performed for lung cancer. However, lung cancer is still the leading cause of cancer-related mortality. Immunotherapy has recently emerged as a very effective new treatment modality, and there is now growing enthusiasm for cancer immunotherapy worldwide. However, the results of clinical studies using immunotherapy are not always favorable. Understanding the steps involved in the recognition ...
#1Solange Peters (UNIL: University of Lausanne)H-Index: 65
#2Peter R. Galle (University of Mainz)H-Index: 105
Last. Nitzan Sternheim (Genentech)
view all 11 authors...
Antibody therapeutics can be associated with unwanted immune responses resulting in the development of anti-drug antibodies (ADA). Optimal methods to evaluate the potential effects of ADA on clinical outcomes in oncology are not well established. In this study, we assessed efficacy and safety, based on ADA status, in patients from over 10 clinical trials that evaluated the immune checkpoint inhibitor atezolizumab as a single agent or as combination therapy for several types of advanced cancers. ...